Wang Gang, Sun Yubei, He Yifu, Ji Chushu, Hu Bing, Sun Yuping
Department of Oncology, Jinan Central Hospital, Shandong University Jinan 250013, Shandong, China ; Department of Oncology, Anhui Medical University Affiliated Anhui Provincial Hospital Hefei 230000, Anhui, China.
Department of Oncology, Anhui Medical University Affiliated Anhui Provincial Hospital Hefei 230000, Anhui, China.
Int J Clin Exp Pathol. 2015 Jan 1;8(1):337-44. eCollection 2015.
MicroRNAs (miRNAs) are a class of small, non-coding RNAs, which have demonstrated to important gene regulators, and have critical roles in diverse biological processes including cancer cell proliferation. Previous studies suggested microRNA-338-3p (miR-338-3p) was down-regulated and play tumor suppressor roles in gastric cancer, colorectal carcinoma and lung cancer. However, the role of miR-338-3p in hepatocellular carcinoma (HCC) is still unclear. In this study, we analyzed the expression of miR-338-3p in HCC tissues and HCC cell lines. We find that miR-338-3p was downregulated in HCC tissues and cell lines. Then functional studies demonstrate ectopic miR-338-3p expression significantly suppressed the in vitro proliferation and colony formation of HCC cells and cause to cell cycle arrest. Using bio-informatic method and report assay we identified a novel miR-338-3p target, FOXP4 in HCC cells. Furthermore, knockdown of FOXP4 have the similar effects in HCC corrected with miR-338-3p. These findings suggest that miR-338-3p regulates survival of HCC cells partially through the downregulation of FOXP4. Therefore, targeting with the miR-338-3p/FOXP4 axis might serve as a novel therapeutic application to treat HCC patients.
微小RNA(miRNA)是一类小的非编码RNA,已被证明是重要的基因调节因子,在包括癌细胞增殖在内的多种生物学过程中发挥关键作用。先前的研究表明,微小RNA-338-3p(miR-338-3p)在胃癌、结直肠癌和肺癌中表达下调并发挥肿瘤抑制作用。然而,miR-338-3p在肝细胞癌(HCC)中的作用仍不清楚。在本研究中,我们分析了miR-338-3p在HCC组织和HCC细胞系中的表达。我们发现miR-338-3p在HCC组织和细胞系中表达下调。随后的功能研究表明,异位表达miR-338-3p可显著抑制HCC细胞的体外增殖和集落形成,并导致细胞周期停滞。使用生物信息学方法和报告分析,我们在HCC细胞中鉴定出一个新的miR-338-3p靶标FOXP4。此外,敲低FOXP4在HCC中具有与miR-338-3p类似的作用。这些发现表明,miR-338-3p部分通过下调FOXP4来调节HCC细胞的存活。因此,靶向miR-338-3p/FOXP4轴可能成为治疗HCC患者的一种新的治疗方法。